Precision radiopharmaceuticals company adopts AbnomX technology: PRECIRIX

AbnomX is pleased to welcome PRECIRIX, a clinical-stage biotechnology company developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments.

The single-domain antibody targets the cancer in minutes after IV infusion anywhere in the body. PRECIRIX will use the Antibody-Extractor™ algorithms with dedicated VHH functionality to strengthen its discovery programmes.

PRECIRIX will benefit from AbnomX’s decades of nanobody experience.